SSR-125543
SSR-125543 had been in phase II clinical trials by Sanofi for the treatment of Post-traumatic stress disorder. It is also in phase I trials for the treatment of anxiety.
The compound had also been in phase II clinical trials for the treatment of major depression. However, in 2011, the research was discontinued.
General Information
Update Date：2015-09-24
- Drug Name：
- SSR-125543
- Research Code：
- SSR-125543; SSR-125543A
- Trade Name：
- MOA：
- CRF1 receptor antagonist
- Indication：
- Major depressive disorder (MDD)
- Status：
- Phase II (Discontinued)
- Company：
- Sanofi (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-09-24
|
Molecular Weight | 519.50 | ||||||||||||
| Formula | C27H28ClFN2OS●HCl | |||||||||||||
| CAS No. |
752253-39-7 (SSR 125543); 321839-75-2 (SSR 125543A); |
|||||||||||||
| Chemical Name | 2-Thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl-, hydrochloride (1:1) | |||||||||||||
| SSR 125543 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||